1. Arnon R, Sela M (1982) In vitro and in vivo efficacy of conjugates of daunomycin with anti-tumor antibodies. Immunol Rev 62: 5–27
2. Atsumi R, Endo K, Kakutani T, Takakura Y, Hashida M, Sezaki H (1987) Disposition characteristics of mytomycin C-dextran conjugate in normal and tumor bearing muscles of rabbits. Cancer Res 47: 5546–5551
3. Davis SS, Illum L (1986) Colloidal delivery systems-opportunities and challengers. In: Tomlinson E, Davis SS (eds) Site-specific drug delivery: cell biology. Medical and pharmaceutical aspects. Wiley, Chichester, pp 93–110
4. Dillman RO, Johnson DE, Shawler DL, Koziol JA (1988) Supeority of an acid-labile daunomycin-monoclonal antibody immunoconjugate compared to free drug. Cancer Res 48: 6097–6102
5. Ebina T, Ohtsuki K, Seto M, Ishida N (1975) Specific G2 block in Hela-S3 cells by neocarzinostatin. Eur J Cancer 11: 155–158